Outset Medical (NASDAQ:OM) Rating Lowered to “Sell” at Wall Street Zen

Outset Medical (NASDAQ:OM) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

A number of other equities analysts also recently commented on OM. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a research report on Wednesday, December 17th. Stifel Nicolaus reduced their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Outset Medical has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Outset Medical Stock Up 2.5%

OM opened at $4.50 on Friday. Outset Medical has a 1 year low of $3.10 and a 1 year high of $21.98. The firm has a 50 day moving average price of $4.43 and a 200 day moving average price of $9.86. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The company has a market cap of $81.68 million, a PE ratio of -0.34 and a beta of 2.08.

Insider Buying and Selling

In related news, General Counsel John L. Brottem sold 9,314 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This represents a 20.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $60,385.28. Following the sale, the chief executive officer owned 107,823 shares of the company’s stock, valued at approximately $552,053.76. This trade represents a 9.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 35,989 shares of company stock worth $180,073. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Outset Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Outset Medical by 955.9% during the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after buying an additional 376,196 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Outset Medical during the second quarter worth $78,000. Ensign Peak Advisors Inc lifted its stake in Outset Medical by 272.4% during the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock worth $6,042,000 after purchasing an additional 230,065 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Outset Medical by 662.8% in the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after purchasing an additional 7,344 shares during the period. Finally, Legal & General Group Plc bought a new stake in Outset Medical during the second quarter valued at $34,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.